Altogether, these results suggest that the melanoma xenografts treated with BRAF and MEK inhibitors produce less lactate and are likely to be less glycolytic while responding to treatment A hypothesis is that this reduction in lactate production could be related to a reduced hexokinase (HK-2) activity, and/or to a modification of the activity of other key glycolytic enzymes such as pyruvate kinase dehydrogenase (PDK). Here, MAP2K7 is linked to melanoma.